1 citations
,
April 2024 in “Journal of Pharmaceutical and Pharmacological Sciences” The mouse models are effective for testing new hair loss treatments.
1 citations
,
July 2022 in “JEADV Clinical Practice” New and existing treatments for hair loss show promise, with some being more effective for men and others for women.
December 2025 in “International Journal of Innovative Technologies in Social Science” New treatments for androgenetic alopecia show promise but need more research for validation.
Recent research on androgenetic alopecia focuses on optimizing treatments, with promising new therapies emerging.
July 2024 in “Forum Dermatologicum” Topical treatments for hair loss can be effective but need careful safety evaluation.
There are many treatments for common hair loss, but more trials are needed to decide which are best.
August 2025 in “Journal of Cosmetic Dermatology” Interest in new and personalized treatments for hair loss is growing.
March 2026 in “Frontiers in Pharmacology” New treatments for hair loss show promise but need more testing for effectiveness and safety.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” Androgenetic alopecia treatments are becoming more personalized and include new therapies like topical antiandrogens and regenerative strategies.
March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)” De nouvelles thérapies promettent de mieux traiter la perte de cheveux due à l'alopécie androgénétique.
January 2025 in “Annals of Dermatology” New treatments for hair loss include low-dose oral minoxidil, light therapy, and innovative therapies targeting hair growth mechanisms.
4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
November 2012 in “Journal of Clinical Pathology” December 2025 in “Biomolecules” Compound 7p shows strong potential as an anticancer agent.
9 citations
,
March 2024 in “Journal of Biomaterials Applications” Rizatriptan benzoate-loaded dissolving microneedles are effective and convenient for treating acute migraines.
15 citations
,
January 2020 in “RSC advances” The new palladium catalyst is effective and reusable for making pharmaceutical ingredients.
October 2025 in “Frontiers in Endocrinology” Methimazole for hyperthyroidism has known and new side effects needing more study for safety.
2 citations
,
November 2022 in “Biosensors” A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.
5 citations
,
January 2024 in “Crystals” The salts have diverse molecular packing with significant hydrogen interactions.
1 citations
,
May 2025 in “Journal of the Indian Chemical Society” July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
August 2008 in “European Neuropsychopharmacology” RY-023, a specific drug, can improve early stage memory learning without affecting general activity in rats, but it's less effective for later learning stages and doesn't impact memory recall.
17 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
April 2023 in “Journal of Investigative Dermatology” PX-12 may help treat psoriasis by blocking inflammation and cell death.
December 2006 in “The Brown University Psychopharmacology Update” Second-generation antipsychotics offer no significant benefit over first-generation ones for schizophrenia.
The research created new azasteroids and pseudoazulenyl nitrones, which could be useful in medicine.
A rigid compound with a common structural motif was successfully synthesized.
6 citations
,
September 2015 in “Journal of Medicinal Chemistry” The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.